Neuphoria Therapeutics Confirms Acquisition Discussions with Scancell
NEUP sits 26% above its 52-week low of $3.645 on elevated volume (3.7× avg).
Summary
Neuphoria Therapeutics confirmed it is in discussions regarding a potential acquisition by Scancell. This highly material development follows a significant Phase 3 trial setback for its BNC210 drug in May, which had negatively impacted the company. An acquisition could offer a substantial premium for shareholders and a strategic path forward, with Scancell potentially becoming NASDAQ-listed through the transaction. Investors will now focus on any further updates regarding these ongoing discussions.
At the time of this announcement, NEUP was trading at $4.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.7M. The 52-week trading range was $3.65 to $21.40. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.